Vera Reports Positive Final Results From TRUTAKNA Kidney Trial
The ORIGIN 3 analysis met all prespecified endpoints, as Vera plans a supplemental FDA filing later this year.
Makkler Newsroom · Oct 22, 07:19 PM · 1 min read
Vera Therapeutics, Inc. Class A VERA
NASDAQHealth TechnologyUnited States
$28.10-0.94 (-3.24%)
Market closed· · USD · Data may be delayed
- Day's range
- 27.8528.96
- 52-week range
- 26.3856.05
Financial health
– / 5
Analyst view · 14 firms
Buy12 buy · 2 hold · 0 sell
Avg. target $71.36 (+153.9%)
Prices may be delayed and are for informational purposes only - not investment advice.